Prostate Cancer Industry, March 2015 Market Reports from Top Publishers

You might be interested in: Drug, Diagnostics, Oncology, Biomarker, Biopsy Device, Healthcare, Hormone, Pharmaceutical, Molecular Diagnostic, Urology Device, Cancer Diagnostic, Clinical Trial, Vaccine.


 
1-10 of 74 reports for Prostate Cancer

Purchase Reports From Reputable Market Research Publishers

Prostate Cancer Partnering 2010-2015

Prostate Cancer Partnering 2010-2015

  • $ 995
  • Industry report
  • March 2015
  • by Currentpartnering

The Prostate cancer Partnering 2010-2015 report provides understanding and access to the prostate cancer partnering deals and agreements entered into by the worlds leading healthcare companies. Trends ...

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight’s, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive ...

Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight’s, “Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed ...

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight’s, “Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides ...

Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight’s, “Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs ...

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015

  • $ 2 000
  • Industry report
  • January 2015
  • by Global Markets Direct

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Hormone Refractory (Castration Resistant, Androgen-Independent) ...

Metastatic Prostate Cancer - Pipeline Review, H1 2015

Metastatic Prostate Cancer - Pipeline Review, H1 2015

  • $ 2 000
  • Industry report
  • January 2015
  • by Global Markets Direct

Metastatic Prostate Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Metastatic Prostate Cancer - Pipeline Review, H1 2015’, provides an overview of the Metastatic Prostate Cancer’s ...

Prostate Cancer Drug Pathway Analyzer 2015

Prostate Cancer Drug Pathway Analyzer 2015

  • $ 2 249
  • Industry report
  • January 2015
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 413 targeted molecular therapies known to affect more than 249 specific intracellular signaling pathways ...

Prostate Cancer Drug Pipeline Update 2015

Prostate Cancer Drug Pipeline Update 2015

  • $ 2 249
  • Industry report
  • January 2015
  • by Bioseeker

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various ...

Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • November 2014
  • by GBI Research

Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The prostate cancer pipeline is among the largest in the ...

About 5 100 reports for Prostate Cancer

Download Unlimited Documents from Trusted Public Sources

Prostate Cancer Industry in Sweden

  • July 2013
    8 pages
  • Prostate Cancer  

    Cancer  

  • Sweden  

    United States  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.